Insider Selling: BioNTech (NASDAQ:BNTX) CEO Sells $4,077,450.00 in Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 41,000 shares of the firm’s stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $99.45, for a total transaction of $4,077,450.00. Following the completion of the transaction, the chief executive officer owned 602,209 shares in the company, valued at approximately $59,889,685.05. The trade was a 6.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Friday, September 11th, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $96.93, for a total value of $4,361,850.00.
• On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The shares were sold at an average price of $96.31, for a total value of $1,974,355.00.
• On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The stock was sold at an average price of $97.78, for a total value of $3,520,080.00.
• On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The shares were sold at an average price of $99.20, for a total value of $3,670,400.00.
• On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The shares were sold at an average price of $103.52, for a total transaction of $3,260,880.00.
• On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $102.85, for a total transaction of $4,628,250.00.

BioNTech Stock Performance

Shares of BNTX stock traded up $2.13 during trading hours on Monday, reaching $98.86. The stock had a trading volume of 1,212,282 shares, compared to its average volume of 1,111,191. The firm has a market capitalization of $25.00 billion, a PE ratio of -12.63 and a beta of 1.29. The firm has a 50-day simple moving average of $96.98 and a 200-day simple moving average of $95.27. BioNTech SE Sponsored ADR has a twelve month low of $79.52 and a twelve month high of $124.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The firm had revenue of $122.31 million for the quarter, compared to analyst estimates of $180.18 million. During the same period in the previous year, the firm earned ($1.60) earnings per share. The company’s revenue for the quarter was down 59.5% on a year-over-year basis. As a group, equities analysts forecast that BioNTech SE Sponsored ADR will post -6.33 earnings per share for the current year.

Hedge Funds Weigh In On BioNTech

Large investors have recently made changes to their positions in the business. Larson Financial Group LLC grew its stake in shares of BioNTech by 86.4% in the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after purchasing an additional 127 shares during the last quarter. Integrated Wealth Concepts LLC bought a new stake in BioNTech during the second quarter worth approximately $39,000. Caitong International Asset Management Co. Ltd grew its position in BioNTech by 1,012.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 556 shares of the company’s stock worth $53,000 after buying an additional 506 shares during the last quarter. Vestcor Inc acquired a new position in BioNTech in the fourth quarter worth approximately $153,000. Finally, Rockefeller Capital Management L.P. lifted its position in shares of BioNTech by 328.6% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,856 shares of the company’s stock valued at $177,000 after acquiring an additional 1,423 shares during the last quarter. Institutional investors own 15.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on BNTX. Sanford C. Bernstein reissued a “market perform” rating on shares of BioNTech in a research note on Friday, June 5th. BMO Capital Markets downgraded shares of BioNTech from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $128.00 to $105.00 in a report on Tuesday, September 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a research note on Monday, July 6th. Jefferies Financial Group restated a “buy” rating on shares of BioNTech in a research report on Monday, June 1st. Finally, UBS Group raised shares of BioNTech from a “neutral” rating to a “buy” rating and upped their price target for the stock from $117.00 to $135.00 in a research note on Wednesday, May 27th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $126.00.

BioNTech Company Profile

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.